2025-12-07 - Analysis Report
Okay, here's a breakdown of the LLY (Eli Lilly and Co.) data, along with analysis.

**0. Report and Analysis Structure**

*   First, simple numerical data is presented.
*   Following each section, a straightforward analysis of the data is provided.
*   Finally, a comprehensive summary combines the findings.

**1. Return Rate Comparison (LLY vs. VOO)**

*   **Ticker:** LLY (Eli Lilly and Co) - A global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products.
*   **LLY Cumulative Return:** 291.31%
*   **VOO (S&P 500) Cumulative Return:** 100.58%
*   **Divergence:**
    *   Current Divergence: 207.5
    *   Relative Divergence: 85.5 (meaning the current divergence is at the 85.5th percentile of its historical range)

**Analysis:**

LLY has significantly outperformed the S&P 500. The current divergence is very high (85.5 relative divergence), suggesting a considerable level of outperformance compared to its historical trend relative to the S&P 500. This indicates that LLY is currently exhibiting stronger growth characteristics compared to the overall market.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2015-2017  | 11.0%   | 76.1% | -17.0%  | -0.0  | 74.0   |
| 2016-2018  | 39.0%   | 68.9% | 24.0%   | -0.0  | 101.4  |
| 2017-2019  | 41.0%   | 68.9% | 19.0%   | 0.4   | 115.2  |
| 2018-2020  | 34.0%   | 79.8% | 10.0%   | 0.4   | 147.9  |
| 2019-2021  | 53.0%   | 79.8% | 7.0%    | 0.5   | 242.1  |
| 2020-2022  | 64.0%   | 79.8% | 65.0%   | 0.4   | 320.6  |
| 2021-2023  | 125.0%  | 78.9% | 124.0%  | 0.2   | 510.8  |
| 2022-2024  | 134.0%  | 81.2% | 113.0%  | 0.2   | 676.5  |
| 2023-2025  | 183.0%  | 83.5% | 118.0%  | 0.2   | 905.7  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Shows strong and increasing growth in recent periods, especially from 2021 onwards.
*   **MDD (Maximum Drawdown):**  Indicates significant downside risk, consistently high across all periods.
*   **Alpha:** The most recent Alpha values are exceptional, demonstrating significant outperformance relative to the market.  The surge in Alpha coincides with the surge in CAGR.
*   **Beta:** Beta values are low (near zero, then 0.4, then 0.2), suggesting LLY's price is not strongly correlated with the overall market. Recent decrease indicates further reduction of market risk.
*   **Cap(B) (Market Capitalization in Billions):**  Shows substantial growth in market capitalization, reflecting investor confidence and company performance.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 1033.56
*   **Last Market Data:** Price: 1010.31, Previous Close: 1014.49, Change: -0.41
*   **5-day SMA:** 1059.38
*   **20-day SMA:** 1024.51
*   **60-day SMA:** 876.08

**Analysis:**

*   The current price (1033.56) is below the 5-day SMA (1059.38), indicating a potential short-term downward trend.
*   The price is above the 20-day SMA (1024.51) and significantly above the 60-day SMA (876.08), suggesting a strong overall upward trend.
*   The last market data shows a slight decrease (-0.41), reinforcing the short-term downward trend observation.

**3. RSI, PPO, and Expected Return Analysis**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 54.19
*   **PPO:** -0.93
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent Divergence Change:** 1.1 (+) indicating a short-term upward trend.
*   **Expected Return:** 47.1% (over 2 years, compared to S&P 500)

**Analysis:**

*   **MRI:**  Suggests a moderate level of risk and recommends a medium investment strategy.
*   **RSI:** An RSI of 54.19 is neutral, not indicating overbought or oversold conditions.
*   **PPO:** A negative PPO (-0.93) can indicate a slightly weakening momentum, but should be considered in the context of the overall trend.
*   **Hybrid Signal:** The system suggests buying, indicating positive confidence.
*   **Expected Return:** The very high expected return suggests strong confidence in LLY's future performance relative to the market.
*   The recent divergence change supports the possibility of a short term upward trend.

**4. Recent News & Significant Events**

*   **Negative Sentiment:** "Would You Still Hold Eli Lilly Stock If It Fell Another 30%?" and "Eli Lilly shares fell for seven consecutive sessions" signal concerns about potential downside risk.
*   **Positive Sentiment:** "Eli Lilly Stock (LLY) Gets Multiple Price Target Increases as Rally Continues", "1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year" and "Eli Lilly and Company (LLY) Stock: Gains Expanded FDA Approval for Jaypirca" show analyst and market optimism driven by FDA approval.
*   **Institutional Activity:** "StoneX Group Inc. Buys 2,814 Shares of Eli Lilly and Company $LLY" suggests some institutional confidence, although the share quantity is not very large.

**Analysis:**

The news is mixed, with some articles raising concerns about potential declines while others highlight positive catalysts like FDA approvals and analyst upgrades. This suggests a degree of uncertainty in the market's short-term view of LLY.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (1.77 on a scale of 1-5)
*   **Opinions:** 27 analysts
*   **Target Price (avg/high/low):** 1056.70 / 1500.00 / 770.00

**Analysis:**

The analyst consensus is strongly bullish, with a "Buy" rating and a target price averaging slightly above the current price. The high target price of $1500 suggests some analysts believe LLY has significant upside potential, while the low target of $770 indicates awareness of downside risks.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-10-30 | 6.22 | 17.60 B$     |
| 2025-08-07 | 6.30 | 15.56 B$     |
| 2025-05-01 | 3.07 | 12.73 B$     |
| 2024-10-30 | 1.08 | 11.44 B$     |
| 2025-10-30 | 1.08 | 11.44 B$     |

**Analysis:**

*   Both EPS and Revenue show strong growth over the recent quarters.  The growth in revenue is consistent, and EPS has seen a dramatic increase in the most recent reports. This indicates strong operational performance and increasing profitability.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B    | 82.91%        |
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $23.79B    | 23.46% |
| 2025-06-30   | $18.27B    | 30.98% |
| 2025-03-31   | $15.76B    | 17.50% |
| 2024-12-31   | $14.19B    | 31.07% |
| 2024-09-30   | $14.24B    | 6.81%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue has consistently increased over the past five quarters, accompanied by very high and stable profit margins. This indicates strong pricing power and efficient operations.
*   **Capital and Profitability:** Equity has grown significantly, indicating retained earnings and reinvestment. ROE (Return on Equity) is volatile but generally high, suggesting efficient use of shareholder equity to generate profits.

**7. Comprehensive Analysis**

Eli Lilly (LLY) presents a mixed picture of very strong fundamentals and some potential short-term concerns.

*   **Strengths:**
    *   Exceptional outperformance against the S&P 500, driven by strong recent Alpha.
    *   High CAGR and growing market capitalization.
    *   Strong and growing revenues and high-profit margins.
    *   Bullish analyst consensus.
    *   High expected future returns.

*   **Weaknesses/Concerns:**
    *   High Maximum Drawdown indicates significant downside risk.
    *   Recent price decline and negative news sentiment suggesting potential short-term volatility.
    *   PPO indicating slightly weakening momentum.

*   **Overall:**

LLY appears to be a fundamentally strong company with significant growth potential, driven by successful products and efficient operations. However, investors should be aware of the inherent downside risk and potential short-term volatility. The analyst consensus and expected return suggest continued optimism, but it is important to monitor the news flow and price action closely for any significant changes in sentiment.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.